Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

High levels of lipoprotein (a)[Lp (a)], an apoB100-containing lipoprotein, are an independent
and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms …

Background Lipoprotein (a) is a presumed risk factor for atherosclerotic cardiovascular
disease. Olpasiran is a small interfering RNA that reduces lipoprotein (a) synthesis in the …

Objective: Lp (a)(lipoprotein [a]) concentrations are associated with atherosclerotic
cardiovascular disease (ASCVD), and new therapies that enable potent and specific …

Importance Lipoprotein (a)(Lp [a]) is a low-density lipoprotein (LDL) cholesterol–like particle
bound to apolipoprotein (a). This novel marker of cardiovascular disease acts through …

There is a need to identify high-risk features that predict early-onset atherosclerotic
cardiovascular disease (ASCVD). The authors provide insights to help clinicians identify and …

Despite the decades-old knowledge that diabetes mellitus is a major risk factor for
cardiovascular disease, the reasons for this association are only partially understood. While …

The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical
activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders …

Background Current guidelines target low-density lipoprotein cholesterol (LDL-C)
concentrations to reduce atherosclerotic cardiovascular disease (ASCVD) risk, and yet …

Background High lipoprotein (a) concentrations present in 10%–20% of the population have
long been linked to increased risk of ischemic cardiovascular disease. It is unclear whether …